Brief: GlycoMimetics Q3 basic EPS USD -0.14
03/11/2023 11:02
Nov 3 (Reuters) - GlycoMimetics Q3 net income USD -9.203 million. * Q3 income from operations USD -9.814 million * Q3 basic EPS USD -0.14
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering